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ABSTRACT 
Treatment of tumors with nanoparticles and combined drugs tend to turn effective as it can sustain for a longer time in the recipient’s body and 
also improve the impact. The conjugates that have proven to have high cytotoxicity are suggested in this report. Pegylation is an advanced drug 
delivery system that maximizes the immunity of the patient and helps in the correct targeting of the affected cells.  
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Introduction 
Drug delivery system is effective since long to treat patients 
with different disorders. The drug delivery methods have 
changed with the introduction of new technologies like 
nanotechnology1-3. Single and combined drug methodologies 
are used to overcome multidrug resistance and make the 
nanomedicine infusion process effective. This co-delivery is 
observed to offer the clinical advantage and improved 
efficiency thereby adding ease to the treatment of cancer 
patients4-8. This review paper begins with the conjugates 
that are used for single and combined drug delivery followed 
by the effectiveness of co-delivery therapy technique. The 
last section of the report discusses the applications of the co-
delivery method in the field of biomedicine.  
Conjugates for single and combined drug delivery 
The modern society has reported a high number of cases 
affected by cancer. Chemotherapy is a commonly used 
treatment for cancer. However, there are issues with the 
dosage and targeting. Camptothecin is one conjugate that can 
be used with the inhibitor and diluted with dimethyl 
sulfoxide. To build a self-assembly structure, camptothecin is 
conjugated with short oligo ethylene glycol. This can enable 
the patient to overcome drug resistance9-13.  
Similar to these conjugates, the nanoparticles that originate 
from the polymer self-assembly are highly effective. The end 
conjugate develops a spherical nanoparticle that has up to 8 
active drugs. In addition to camptothecin, disulfide bonding 
is used to crosslink with the nanoparticles and this act as a 
nano drug delivery system14-17. In some instances, paclitaxel 
and camptothecin are conjugated to develop a beta sheet 
forming multiple compounds and peptides. The advantage 
with this bond is that it self-assembles into nanostructures18-
21. This conjugate can release the cancer cause agents and 
eliminate cervical cancer cell from the body. This conjugation 
can also help overcome drug resistance.  
Not just restricted to the tumor, co-delivery can be a better 
option for treating breast cancer. Multiple polymers are 
combined and infused via the nanosized drug delivery 
system. Mitoxantrone is one anticancer agent that is already 
in use in the clinic since the past. Now, this is combined with 
covalent to improve efficiency22-25. Redox-triggered MTO 
prodrug performs a controlled drug release and improves 
the therapeutic effect. This amphiphilic MTO prodrug is a 
combination of MTO and TPGS where the micelles are self-
assembled26-29. 
 
Zhang et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2019; 9(1-s):377-380 
ISSN: 2250-1177                                                                                  [378]                                                                                 CODEN (USA): JDDTAO 
 
Figure 1: Schematic diagram of self-assembly, tumor targeting, redox-sensitive MTO release responding to the intracellular high 
level and inhibition of P-gp efflux of TPGS-based prodrug micelles 
 
This combination has brought better apoptosis promoting 
action. Further, the drug efflux rate is decreased, and drug 
resistance is controlled for the patient. When a single drug is 
induced, the patient does not see significant development. 
However, a co-therapy has multiple advantages with no 
accumulation of additional cancer or tumor-causing cells30-33.  
The effectiveness of co-delivery therapy 
Chemotherapy is often hindered due to the multidrug 
resistance problems faced by cancer patients. The cancer 
cells cannot tolerate the injuries induced by the drug. 
Therefore, there is a need for co-administration of various 
chemotherapeutic agents to be applied in the clinic4. It is 
observed that the co-delivery therapy for cancer is a 
promising mechanism as the undesirable toxicity is 
eliminated. Administration of the two drugs - fluorouracil 
and paclitaxel can improve efficiency in the treatment of 
MDR cancer34-38.  
There are multiple ways to enable co-delivery - inducing 
dual chemotherapeutic drugs, with MDR inhibitor and with a 
sensitizer. The MDR inhibitor is a combination of cytotoxic 
drugs and many efflux pump inhibitors. This combination 
can maintain cytotoxicity and improve pharmacokinetic 
properties. The most promising inhibitor is tariquidar as this 
can sensitize those resistant cell lines and control the 
overexpression of P-gp22,24,39,40.  
On the other hand, sensitizer compounds can fix the 
dysfunctional apoptotic signaling with chemotherapeutic 
drugs. Curcumin is yet another polyphenol that engages in 
anticancer activity and also down regulates the pathways 
from functioning and progressing the cancer cells further to 
other parts. It is observed that the co-delivery has a higher 
potential to control MDR and this only requires the proper 
selection of the nanotherapeutic delivery system to choose 
inhibitor/ sensitizer/ modulator9-11,37. 
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Pegylated drug delivery applications 
Drug delivery has now got different methods to reach the 
targeted cells and use inhibitors to control the activity of 
attacking molecule. Pegylation is a procedure where 
polyethylene glycol (PEG) (hydrophilic) is attached to the 
therapeutic molecule. This attachment improves 
hydrophilicity and also keeps up the activity of enzymes29,30. 
Pegylation typically includes hydroxyl groups, and PEG is 
attached to liposome/protein/peptide/polymersome. The 
application of PEG does not show high toxicity level. It has so 
far proved to be safe to the humans.  
The only drawback with this delivery system is the choice of 
molecules to influence the pharmacokinetics. Pegylation is a 
favorite technique to deliver drugs to the end body30. It is a 
model that is used in genetic engineering as well as several 
in vivo and in vitro applications. The other advantage with 
pegylation is that it can increase the half-life of vectors. As a 
result, the circulation times increases and the impact is 
longer. The concerned health problem is reduced. 
Conclusion 
The types of drug deliveries are numerous in the market. 
Nanomedicine is a field that encourages a play with 
nanoparticles to treat multiple health disorders. From the 
observation in this review sheet, it is known that co-delivery 
of therapeutic drugs can increase the effectiveness and the 
targeted delivery is feasible. The conjugate has to be chosen 
carefully. This drug delivery requires expert knowledge. 
Otherwise, it has a widespread application in the treatment 
of cancer and tumors and can be the future of the medical 
field.  
References 
1. Kang, C., Qin, J., Osei, W. & Hu, K. Age-dependent Mitochondrial 
Targeting Of Protein Kinase C Epsilon In Cardioprotection. The 
FASEB Journal 2017. 
2. Han, R., Sun, Y., Kang, C., Sun, H. & Wei, W. Amphiphilic dendritic 
nanomicelle-mediated co-delivery of 5-fluorouracil and 
doxorubicin for enhanced therapeutic efficacy. Journal of Drug 
Targeting 2017; 25:140-148. 
3. Duan, Y., et al. Bioactivity evaluation-based ultra high-
performance liquid chromatography coupled with electrospray 
ionization tandem quadrupole-time-of-flight mass spectrometry 
and novel distinction of multi-subchemome compatibility 
recognition strategy with Astragali Radix-Fructus Corni herb-
pair as a case study. J Pharm Biomed Anal 2016; 129:514-534. 
4. Sun, Y., et al. Co-delivery of dual-drugs with nanoparticle to 
overcome multidrug resistance. European Journal of BioMedical 
Research 2016; 2:12-18. 
5. Ai, R., et al. Comprehensive epigenetic landscape of rheumatoid 
arthritis fibroblast-like synoviocytes. Nat Commun 2018; 9:1921. 
6. Fan, S., et al. Computationally expanding infinium 
HumanMethylation450 BeadChip array data to reveal distinct 
DNA methylation patterns of rheumatoid arthritis. 
Bioinformatics 2016; 32:1773-1778. 
7. Liu, F., Sun, Y. & Kang, C. Controlling Amphiphilic Functional 
Block Copolymers’ Self-Assembly: From Structure to Size. 
(2016). 
8. Song, L., et al. Crocetin inhibits lipopolysaccharide-induced 
inflammatory response in human umbilical vein endothelial 
cells. Cellular Physiology and Biochemistry 2016; 40:443-452. 
9. Sun, Y., Kang, C., Liu, F. & Song, L. Delivery of antipsychotics with 
nanoparticles. Drug Development Research 2016; 77:393-399. 
10. Kang, C., et al. Delivery of nanoparticles for treatment of brain 
tumor. Current Drug Metabolism 2016; 17:745-754. 
11. Xue, X., et al. Discovery of novel inhibitors disrupting HIF-
1α/von Hippel–Lindau interaction through shape-based 
screening and cascade docking. PeerJ 2016; 4:e2757. 
12. Hersch, S.J., et al. Divergent protein motifs direct elongation 
factor P-mediated translational regulation in Salmonella enterica 
and Escherichia coli. MBio 2013; 4:e00180-00113. 
13. Shuhong, X., et al. Dynamic expression of AQP4 in early stageof 
ischemia/reperfusion rats and cerebral edema. Chinese 
Pharmacological Bulletin 2016; 32:1433-1441. 
Zhang et al                                                                                                           Journal of Drug Delivery & Therapeutics. 2019; 9(1-s):377-380 
ISSN: 2250-1177                                                                                  [380]                                                                                 CODEN (USA): JDDTAO 
14. Peng, J., et al. Enhanced Liver Regeneration After Partial 
Hepatectomy in Sterol Regulatory Element-Binding Protein 
(SREBP)-1c-Null Mice is Associated with Increased 
Hepatocellular Cholesterol Availability. Cellular Physiology and 
Biochemistry 2018; 47:784-799. 
15. Yang, Z., et al. Functional exosome-mimic for delivery of siRNA to 
cancer: in vitro and in vivo evaluation. Journal of Controlled 
Release 2016; 243:160-171. 
16. Kang, C., Hernandez, V.A. & Hu, K. Functional interaction of the 
two-pore domain potassium channel TASK-1 and caveolin-3. 
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 
2017; 1864:1537-1544). 
17. Waller, A.P., et al. GLUT12 functions as a basal and insulin-
independent glucose transporter in the heart. Biochimica et 
Biophysica Acta (BBA)-Molecular Basis of Disease 2013; 
1832:121-127. 
18. Li, Q., et al. Identification by shape-based virtual screening and 
evaluation of new tyrosinase inhibitors. PeerJ 2018; 6:e4206. 
19. Chen, Y., et al. Identification of 4-aminoquinoline core for the 
design of new cholinesterase inhibitors. PeerJ 2016; 4:e2140. 
20. Kang, C. & Hu, K. Impact of hypoxia in the expression and 
regulation of the TASK-1 potassium channel in cardiac myocytes. 
The FASEB Journal 2016; 30:lb598-lb598. 
21. Kang, C. Ion channels, protein kinase C and caveolae in 
cardioprotection, (The Ohio State University, 2015). 
22. Qiao, H., et al. Redox-triggered mitoxantrone prodrug micelles 
for overcoming multidrug-resistant breast cancer. Journal of 
drug targeting 2018; 26:75-85. 
23. Kang, C., Qin, J., Osei, W. & Hu, K. Regulation of protein kinase C-
epsilon and its age-dependence. Biochemical and Biophysical 
Research Communications 2017; 482:1201-1206. 
24. Sun, Y., et al. RGD Peptide‐Based Target Drug Delivery of 
Doxorubicin Nanomedicine. Drug development research 2017; 
78:283-291. 
25. Kang, C. & Hu, K. Role of caveolin-3 in adenosine-induced 
increase in mitochondrial PKCε. The FASEB Journal 2013; 
27:1191.1197-1191.1197. 
26. Kang, C. & Hu, K. Modulation of the two-pore domain potassium 
channel TASK-1 by caveolin-3. The FASEB Journal 2015; 
29:845.814. 
27. Davis, M.E., Chen, Z.G. & Shin, D.M. Nanoparticle therapeutics: an 
emerging treatment modality for cancer. Nat Rev Drug Discov 
2008; 7:771-782. 
28. Kang, C., Sun, Y., Wang, M. & Cheng, X. Nanosized camptothecin 
conjugates for single and combined drug delivery. European 
Journal of BioMedical Research 2016; 2:8-14. 
29. Qiao, H., et al. Orally delivered polycurcumin responsive to 
bacterial reduction for targeted therapy of inflammatory bowel 
disease. Drug Delivery 2017; 24:233-242. 
30. Liu, F., Sun, Y., Kang, C. & Zhu, H. Pegylated Drug Delivery 
Systems: From Design to Biomedical Applications. Nano LIFE 
2016; 6:1642002. 
31. Sun, Y., Kang, C., Yao, Z., Liu, F. & Zhou, Y. Peptide-Based Ligand 
for Active Delivery of Liposomal Doxorubicin. Nano Life 2016; 
6:1642004. 
32. Yeh, C.Y., Hsiao, J.K., Wang, Y.P., Lan, C.H. & Wu, H.C. Peptide-
conjugated nanoparticles for targeted imaging and therapy of 
prostate cancer. Biomaterials 2016; 99:1-15. 
33. Fan, S., Huang, K., Ai, R., Wang, M. & Wang, W. Predicting CpG 
methylation levels by integrating Infinium 
HumanMethylation450 BeadChip array data. Genomics 2016; 
107:132-137. 
34. Cheng, X. & Lee, R.J. The role of helper lipids in lipid 
nanoparticles (LNPs) designed for oligonucleotide delivery. Adv 
Drug Deliv Rev 2016; 99:129-137. 
35. Sun, Y. & Kang, C. Self-Assembly of Peptides into Hydrogel. 
Journal of Organic & Inorganic Chemistry 2016; 2:5. 
36. Yao, Z., Sun, Y. & Kang, C. Structure and self-assembly of 
multicolored Naphthalene Diimides Semiconductor. Nano LIFE 
2016; 6: 1642007. 
37. Cheng, X., et al. T7 Peptide-Conjugated Lipid Nanoparticles for 
Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical 
Carcinomas. Molecular pharmaceutics 2018; 15:4722-4732. 
38. Zhong, X., Sun, Y., Kang, C. & Wan, G. The theory of 
dielectrophoresis and its applications on medical and materials 
research. European Journal of BioMedical Research 2017; 2:7-11. 
39. Yung, B.C., et al. Lipid nanoparticles composed of quaternary 
amine–tertiary amine cationic lipid combination (QTsome) for 
therapeutic delivery of AntimiR-21 for lung cancer. Molecular 
pharmaceutics 2016; 13:653-662. 
40. Cheng, X., et al. Lipid Nanoparticles Loaded with an Antisense 
Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung 
Cancer. Pharmaceutical research 2017; 34:310-320. 
 
